Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by dysregulated myeloid proliferation and hyperactive JAK-STAT signaling pathway. While JAK inhibitors have become standard therapies for the management of these conditions, significant challenges remain due to resistance to these medications and adverse effects such as cytopenias and infectious complications.
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by dysregulated myeloid proliferation and hyperactive JAK-STAT signaling pathway. While JAK inhibitors have become standard therapies for the management of these conditions, significant challenges remain due to resistance to these medications and adverse effects such as cytopenias and infectious complications.
What the study was
- Study design
- Journal Article (unspecified)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Semin Hematol
Why it surfaced
Matched watchlist topic 'Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)'. Study design: Journal Article (unspecified). Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.